Due to the good readthrough activity in preclinical studies and the low toxicity, ataluren was further tested in human clinical trials, including CF, DMD, Dravet Syndrome (DS), CDKL5 Deficiency Syndrome (CDD), and aniridia. Here, CDKL5 is linked to Dravet syndrome.